

**FOR IMMEDIATE RELEASE**

December 14, 2010

Eisai Co., Ltd.  
Sanko Junyaku Co., Ltd.  
SEKISUI MEDICAL CO., LTD.

**Sanko Junyaku and Sekisui Medical Conclude Exclusive Japan Marketing Agreement  
for Influenza Test Kit RapidTesta® FLU II**

Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President & CEO: Keisuke Watanabe, "Sanko Junyaku"), the diagnostics subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), and SEKISUI MEDICAL CO., LTD. (Headquarters: Tokyo, President & CEO: Mutsumi Fukuda, "Sekisui Medical") today signed an exclusive marketing agreement concerning RapidTesta® FLU II ("Kit"), an influenza test kit currently manufactured and marketed by Sekisui Medical. Under the terms of the agreement, Sanko Junyaku will acquire the exclusive right to market the Kit in Japan.

The Kit is a diagnostic test kit used to detect type A and type B influenza virus antigens in nasal suction fluid or from a nasal swab. It requires no special instruments and can be used simply and rapidly at the bedside or in the clinic. The Kit is valuable in that it provides results almost immediately and is noted for its high specificity.

Sanko Junyaku plans to launch the Kit in Japan in the middle on January 2011. With marketing support from Eisai and cooperation from Sekisui Medical, Sanko Junyaku will be able to provide useful information to an even greater number of healthcare professionals to aid in the early diagnosis and treatment of influenza.

Influenza is an acute viral infection that reaches epidemic proportions every winter, as it affects many people. Complications associated with pneumonia in aged patients or with encephalopathy /encephalitis in children, especially, can easily become serious and while these patients tend to have a poor prognosis. In recent years, several anti-viral agents against influenza have been developed, and it has now become possible to reduce the risk of developing complications and serious aggravation by using the appropriate treatment in the early stages of the disease. Accordingly, an early diagnosis of influenza plays an important part in treatment of the disease.

By marketing the Kit, Sanko Junyaku, Eisai and Sekisui Medial seek to make contributions to increasing the benefits provided to influenza patients.

**[Please refer to the following notes for a product outline, company profiles  
and a product photograph]**

<b>Media Inquiries:</b>		
Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120	Public Relations Section, General Affairs Department, Sanko Junyaku Co., Ltd. +81-(0)3-3865-4311	General Affairs Group, General Affairs & Personnel Resources Department, Sekisui Medical Co., Ltd. +81-(0)3-3272-0672

**[Notes to editors]**

■ **Product Outline**

Brand Name	RapidTesta <sup>®</sup> FLU II (Influenza Test Kit)
Indications (Purpose of Use)	To detect type A or type B influenza antigen in nasal suction fluid or from a nasal swab. (To be used predominantly as an ancillary test for the diagnosis of influenza virus infection.)
Shelf Life	Two years following date of manufacture (store between 2~30°C)
National Health Insurance (NHI) Points	(As of December 2010) Laboratory Test Fee            Infectious Immunology Test Influenza Virus Antigens    150 points Laboratory Diagnosis Fee    Immunology Diagnosis Fee   144 points
Suggested Retail Price	23,600 yen (20 tests per kit)
Manufactured and Marketed by	Sekisui Medical Co., Ltd.
Marketed by	Sanko Junyaku Co., Ltd.
Co-marketed by	Eisai Co., Ltd.

■ **Company Outline**

<Eisai Co., Ltd.>

Representative	Haruo Naito
Corporate Address	4-6-10 Koishikawa, Bunkyo-ku, Tokyo
Scope of Business	Development, manufacturing, marketing, import/ export of pharmaceuticals
Capital	44,985 million yen (As of March 31, 2010)

<Sanko Junyaku Co., Ltd.>

Representative	Keisuke Watanabe
Corporate Address	1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo
Scope of Business	Development, manufacturing, marketing, import/export of in-vitro diagnostics, laboratory reagents, laboratory instruments and other supplies
Capital	5,262 million yen (As of March 31, 2010) (100% owned by Eisai Co., Ltd.)

<Sekisui Medical Co., Ltd.>

Representative	Mutsumi Fukuda
Corporate Address	13-5, Nihombashi 3-chome, Chuo-ku, Tokyo
Scope of Business	Diagnostic Reagents, Medical Devices, Pharmaceuticals & Fine Chemicals, ADME & Tox. Research
Capital	1,275 million yen (As of March 31, 2010)

■Product Photograph

